Skip to main content

Table 1 Admission reason and patients’ characteristics

From: Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial

  IVIG (n = 19) Placebo (n = 19) P-value
Admission reason Number of patients
Respiratory failure 7 8 1.00
Cardiopulmonary resuscitation 1 2 1.00
Sepsis/septic shock 9 8 1.00
Cardiogenic shock 1 1 1.00
Coma 1 0 1.00
Age (years) 61 ± 11 66 ± 12 0.18
Gender (female/male) (7/12) (10/9) 0.52
BMI (kg/m2) 28 ± 5 28 ± 6 0.94
SOFA score 11 ± 4 11 ± 5 0.88
APACHE III score 96 ± 28 96 ± 24 0.99
Mortality on Day 14 (non-survivors (%)) 3 (16%) 3 (16%) 1.00
Mortality on Day 28 (non-survivors (%)) 5 (26%) 6 (32%) 1.00
Length of ICU stay (days) 30 ± 16 27 ± 13 0.66
CIP score on Day 0 2.6 ± 1.5 2.0 ± 1.3 0.26
CIM score on Day 0 1.1 ± 0.8 1.4 ± 0.8 0.27
CIPNM severity sum score on Day 0 3.6 ± 1.8 3.4 ± 1.5 0.71
C-reactive protein (mg/dL) on Day 0 13 ± 11 13 ± 8 0.99
Fibrinogen (mg/dL) on Day 0 462 ± 186 563 ± 192 0.11
Leukocytes (G/L) on Day 0 19.4 ± 10.3 18.6 ± 8.7 0.78
  1. Data are means ± SD or absolute counts. APACHE III, Acute Physiology and Chronic Health Evaluation III; BMI, body mass index; CIM, Critical illness myopathy; CIP, Critical illness polyneuropathy; CIPNM, Critical illness polyneuropathy and/or myopathy; IVIG, intravenous immunoglobulin; SOFA, Sequential Organ Failure Assessment score.